Document:

Form of Notice of Stock Option Grant and Agreement for 2003 Directors' Stock

 Exhibit 10.25 
  
 XCYTE THERAPIES, INC. 
  
 2003 DIRECTORS’ STOCK OPTION PLAN 
  
 NOTICE OF STOCK OPTION GRANT 
  
 «Optionee» 
  
 You have been granted an option to purchase Common Stock of Xcyte Therapies, Inc. (the “Company”) as follows: 
  

			
	Date of Grant	  	«GrantDate»
		
	Vesting Commencement Date	  	«VestingStartDate»
		
	Exercise Price per Share	  	«ExercisePrice»
		
	Total Number of Shares Granted	  	«SharesGranted»
		
	Total Exercise Price	  	«TotalExercisePrice»
		
	Expiration Date	  	«ExpirDate»
		
	Vesting/Exercise Schedule	  	This Option shall vest and become exerciseable, according to the following schedule: __________________.
		
	Termination Period	  	This Option may be exercised for 90 days after termination of Optionee’s Continuous Status as a Director, or such longer period as may be applicable upon death or Disability of Optionee
as provided in the Plan, but in no event later than the Expiration Date as provided above.

  

 By your acceptance of this grant, you and the Company agree that this option is granted under and
governed by the terms and conditions of the 2003 Directors’ Stock Option Plan and the Nonstatutory Stock Option Agreement, all of which are provided to you and made a part of this document. 
  

 XCYTE THERAPIES, INC. 
  
 NONSTATUTORY STOCK OPTION AGREEMENT 
  
 1. Grant of Option. The Board of Directors of the Company hereby grants to the Optionee named in the Notice of
Stock Option Grant (the “Optionee”) attached to this Agreement an option (the “Option”) to purchase a number of Shares, as set forth in the Notice of Stock Option Grant, at the exercise price per share set forth in
the Notice of Stock Option Grant (the “Exercise Price”‘), subject to the terms and conditions of the 2003 Directors’ Stock Option Plan (the “Plan”), which is incorporated herein by reference. Capitalized
terms not defined herein shall have the meanings ascribed to such terms in the Plan. In the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this Nonstatutory Stock Option Agreement, the terms and
conditions of the Plan shall prevail. 
  
 2. Exercise of
Option. 
  
 (a) Right to
Exercise. This Option is exercisable during its term in accordance with the Vesting/Exercise Schedule set out in the Notice of Stock Option Grant and the applicable provisions of the Plan and this Nonstatutory Stock Option Agreement. In the
event of Optionee’s death, disability or other termination of Optionee’s service as a Director, the exercisability of the Option is governed by the applicable provisions of the Plan and this Nonstatutory Stock Option Agreement. 

 
 (b) Method of Exercise. This Option is
exercisable by delivery of an exercise notice, in the form attached as Exhibit A (the “Exercise Notice”), which shall state the election to exercise the Option, the number of Shares in respect of which the Option is being
exercised (the “Exercised Shares”), and such other representations and agreements as may be required by the Company pursuant to the provisions of the Plan. The Exercise Notice shall be signed by the Optionee and shall be delivered
in person or by certified mail to the Secretary of the Company. The Exercise Notice shall be accompanied by payment of the aggregate Exercise Price as to all Exercised Shares. This Option shall be deemed to be exercised upon receipt by the Company
of such fully executed Exercise Notice accompanied by such aggregate Exercise Price. 
  
 No Shares shall be issued pursuant to the exercise of this Option unless such issuance and exercise complies with all relevant provisions
of law and the requirements of any stock exchange or quotation service upon which the Shares are then listed. Assuming such compliance, for income tax purposes the Exercised Shares shall be considered transferred to the Optionee on the date the
Option is exercised with respect to such Exercised Shares. 
  
 3.
Method of Payment. Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of the Optionee: 
  
 (a) cash; 
  
 (b) check; 
  

 (c) delivery of a properly executed exercise notice together with such other
documentation as the Administrator and the broker, if applicable, shall require to effect an exercise of the Option and delivery to the Company of the sale or loan proceeds required to pay the exercise price; or 
  
 (d) surrender of other Shares which (i) in the case of
Shares acquired directly or indirectly from the Company, have been owned by the Optionee for more than six (6) months on the date of surrender, and (ii) in any case which have a Fair Market Value on the date of surrender equal to the aggregate
Exercise Price of the Exercised Shares. 
  
 4.
Non-Transferability of Option. This Option may not be sold, pledged, assigned, hypothecated, transferred or disposed of in any manner other than (a) by will or by the laws of descent or distribution; (b) pursuant to a qualified
domestic relations order (as defined by the Code or the rules thereunder); (c) by gift to the Optionee’s Family; or (d) by gift or in exchange for an interest in such entity to (i) a trust in which Optionee and/or Optionee’s Family have
more than fifty percent of the beneficial interest, (ii) a foundation in which Optionee and/or Optionee’s Family control the management of assets, or (iii) any other entity in which Optionee and/or Optionee’s Family own more than fifty
percent of the voting interests. For purposes of this Section 10, Optionee’s “Family” shall include any child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew,
mother-in-law, father-in-law, son-in-law; daughter-in-law, brother-in-law or sister-in-law, including adoptive relationships, and any person sharing the employee’s household (other than a tenant or employee). The designation of a beneficiary by
an Optionee does not constitute a transfer. An Option may be exercised during the lifetime of an Optionee only by the Optionee or a transferee permitted by this Section 4 and Section 10 of the Plan. The terms of the Plan and this Nonstatutory Stock
Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of the Optionee. 
  
 5. Term of Option. This Option may be exercised only within the term set out in the Notice of Stock Option Grant, and may be exercised
during such term only in accordance with the Plan and the terms of this Nonstatutory Stock Option Agreement. 
  
 6. Tax Consequences. Set forth below is a brief summary of certain federal and California tax consequences relating to this Option under the
law in effect as of the date of grant. THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND REGULATIONS ARE SUBJECT TO CHANGE. OPTIONEE SHOULD CONSULT HIS OR HER OWN TAX ADVISER BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES.

  
 (a) Exercising the Option.
Since this Option does not qualify as an incentive stock option under Section 422 of the Code, the Optionee may incur regular federal and California income tax liability upon exercise. The Optionee will be treated as having received compensation
income (taxable at ordinary income tax rates) equal to the excess, if any, of the fair market value of the Exercised Shares on the date of exercise over their aggregate Exercise Price. 
  
 (b) Disposition of Shares. If the Optionee holds the Option Shares for more than one year,
gain realized on disposition of the Shares will be treated as long-term capital gain 

  

 -2- 

 
for federal and California (and other states) income tax purposes. Long-term capital gain will be taxed for federal income tax and alternative minimum tax
purposes at a maximum rate of 20% if the Shares are held more than one year after exercise. 
  
 By your acceptance of this grant, you and the Company agree that this Option is granted under and governed by the terms and conditions of the Plan and this Nonstatutory Stock Option Agreement. Optionee has reviewed
the Plan and this Nonstatutory Stock Option Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Nonstatutory Stock Option Agreement and fully understands all provisions of the Plan and
Nonstatutory Stock Option Agreement. Optionee hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions relating to the Plan and Nonstatutory Stock Option Agreement. 

 

 -3- 

 EXHIBIT A 
  

NOTICE OF EXERCISE 
  

			
		
	To:	  	Xcyte Therapies, Inc.
		
	Attn:	  	Stock Option Administrator
		
	Subject:	  	Notice of Intention to Exercise Stock Option

  
 This is official
notice that
                                       
 (“Optionee”) intends to exercise Optionee’s option to purchase                      shares of Xcyte Therapies,
Inc. Common Stock, under and pursuant to the Company’s 2003 Directors’ Stock Option Plan and the Nonstatutory Stock Option Agreement dated
                        , as follows: 
  

					
	Grant Number:	  	 	  	 
			
	Date of Purchase:	  	 	  	 
			
	Number of Shares:	  	 	  	 
			
	Purchase Price:	  	 	  	 
			
	Method of Payment of
Purchase Price:	  	 	  	 
			
	Social Security No.:	  	 	  	 
		
	The shares should be issued as follows:	  	 

  

							
				
	 Name:
	 	 	  	 	  	 
				
	Address:Amendment No. 6 dated August 2, 2004 to the Services Agreement

 Exhibit 10.39 
  
 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information
subject to the confidentiality request. Omissions are designated as [**]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 
  
 AMENDMENT NO. 6 
  
 TO THE 
  
 SERVICES AGREEMENT 
  
 between 
  
 LONZA
BIOLOGICS PLC. 
  
 and 
  
 XCYTE THERAPIES INC. 
  
 RELATING TO [**] 
  

 THIS AMENDMENT is made the 2nd day of August, 2004 
  
 BETWEEN

  

	1.	Lonza Biologics plc. of 228 Bath Road, Slough, SL1 4DX, Berkshire, England (“LB”) and 

  

	2.	Xcyte Therapies Inc. of 1124 Columbia Street, Suite 130, Seattle, Washington 98104, USA (“Customer”). 

  
 WHEREAS 
  

	A.	The parties have entered into an Agreement dated 6th June 2000 relating to the supply of Services (as therein defined), and 

  

	B.	The parties now wish to amend the terms of the Agreement 

  
 THEREFORE it is hereby agreed by and between the parties that the Agreement shall be amended as follows: - 
  

	1.	Stage 21 shall be added to Schedule 2 as follows: 

  

	  	STAGE 21 - PRODUCTION OF CGMP PRODUCT AT [**] SCALE FOR [**] 

  

							
	21.1	  	Objective	 	 	  	 
			
	 	  	21.1.1	 	To manufacture [**] in accordance with the principles of cGMP. Product to be produced as one lot.
				
	21.2	  	Activities	 	 	  	 
			
	 	  	21.2.1	 	After receiving [**], recover [**] and [**].
				
	 	  	 	 	Note:	  	Cells from two ampoules of the WCB will be recovered and passaged separately. Only cells derived from one ampoule will be used to inoculate the [**].
			
	 	  	21.2.2	 	Perform [**] at [**].
			
	 	  	21.2.3	 	Cryopreserve an [**] for testing as required by the Customer.
			
	 	  	21.2.4	 	Clarify [**].
			
	 	  	21.2.5	 	[**] by procedure established [**].
			
	 	  	21.2.6	 	Test [**] against the [**].
			
	 	  	21.2.7	 	Undertake review of lot documentation and disposition of Product by LB QA group.

  

	[**]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 1 

							
			
	 	  	21.2.8	 	Review requirements (if any) for Process modifications in order to meet Specification for manufacture of subsequent lots. Any such Process modifications are subject to
agreement.
			
	 	  	21.2.9	 	Deliver Product to Customer.
			
	 	  	21.2.10	 	Undertake quality assurance review of lot documentation and issue Certificate of Analysis or other appropriate summary of analysis.
			
	21.3	  	Timescale	 	 
		
	 	  	This Stage will commence as soon as the [**] is available for use and the Process development activities and cGMP documents are complete.
		
	 	  	This Stage shall be complete upon quality assurance review of lot documentation. It is estimated that Product will be delivered [**] from commencement of this Stage. If
Customer requests in writing, the Product can be shipped in quarantine prior to release. It is estimated that this shipment could occur [**] from commencement of this Stage.

  

	2.	Schedule 3, Part 1 shall be amended as follows: 

  

			
	          “Stage 16 Production of cGMP product at [**] for
[**]
	  	£[**]”

  

	3.	Schedule 3, Part 2 Price shall be amended as follows: 

  

	  	“For Stage 16 

	  	[**] on [**] 

	  	[**] upon completion of [**].” 

  

	4.	Save as herein provided all other terms and conditions of the Agreement shall remain in full force and effect. 

  
 IN WITNESS WHEREOF the parties have caused this Amendment to be executed by their
representatives thereunto duly authorized as of the day and year first written. 
  

					
			
	 Signed by
	 	 	 	 /s/ Ronald J. Berenson

	 for and on behalf of Xcyte Therapies Inc.
	 	 	 	 
			
	 Signed by
	 	 	 	 /s/ Judith Symes

	 for and on behalf of Lonza Biologics plc.
	 	 	 	 

  

	[**]	Certain information on this page has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the
omitted portions. 

  

 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00072-of-00352.parquet"}]]